Cellular Therapies for Treating High Risk Haematological Neoplasm

Dear Colleagues,

The availability of CAR-T therapy is changing the treatment landscape of several haematological malignancies and redifining the role of both allogeneic and autologous stem cell transplantants.

With this Special Issue on haematology, we aim to collect manuscripts from real world experiences regarding the management of patients affected with haematological malignancies and candidates for both transplants or CAR-T strategies.

The ultimate goal of this Special Issue is to capture the modification of the role of transplant strategies as a consequence of the availabilities of advanced immune effector cells therapies and also of a better understanding of the mechanisms of the pathogenesis of each disease.

Dr. Daniele Avenoso
Dr. Maurizio Miglino
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Hematology Reports is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• acute leukaemia
• haematopoietic stem cell transplant
• lymphoma
• chronic myeloid leukaemia